Neonatal cardiomyocytes have gained in popularity for drug screening in the past several years due to their tissue-like morphology and spontaneous contraction ability. Myosight™ offers the first high throughput screen to overcome the significant difficulties in utilizing this system including the ability to measure contraction epicenter localization and number and contraction strength.

• Ability to assay viable neonatal cardiomyocytes using visible light through time
• Multiple foci feature allows efficient isolation and quantitation of contraction centers at a rate and sensitivity beyond that possible by unaided observers
• Isolation of foci allows separation between single cell and distributed contractions
• Accurate measurement of contraction strength

Currently in development, Reify has teamed with researchers from Harvard Medical School to bring machine vision to high throughput screening of populations of Zebrafish for drug discovery.

Features :

• Accurate measurement of ventricle function and corresponding blood flow in situ in populations of fish
• Capable of differentiating ventricle and atrium in wild type and mutant zebrafish